Hiscox Executes Further Buyback Acquiring 334,711 Shares in July 2026 as Part of Ongoing Capital Return Strategy

Hiscox’s Continued Capital Allocation via Share Cancellation

On 27 July 2026, Hiscox Limited confirmed the successful completion of another tranche of its share buyback programme, originally authorised on 25 February 2026. During the five trading days from 20 to 24 July 2026, the company acquired 334,711 Ordinary Shares through Peel Hunt LLP. This announcement highlights Hiscox’s transparent capital deployment strategy and its sustained commitment to enhancing shareholder value by systematically reducing the share count.

Share cancellation following buybacks is a common capital management approach among listed companies, especially in the insurance sector. As a specialist underwriter operating across multiple jurisdictions and insurance lines, Hiscox uses this programme to optimise its capital structure. By cancelling repurchased shares rather than holding them in treasury, the company permanently lowers its equity base, potentially delivering dilution-neutral or accretive effects on earnings per share for existing shareholders.

Detailed Daily Purchase Activity and Price Trends Over Five Days

The buyback execution over five consecutive trading days provides detailed insight into Hiscox’s market activity during late July 2026. On 20 July, 67,120 Ordinary Shares were bought at prices between 1,859 pence and 1,864 pence, with a VWAP of 1,861.65 pence—the highest price paid during the period—indicating strong share valuations at the week’s start.

Subsequent days showed a downward price trend: 67,094 shares were acquired on 21 July at 1,834–1,838 pence (VWAP 1,835.17 pence); 68,123 shares on 22 July at 1,828–1,845 pence (VWAP 1,836.89 pence); 64,122 shares on 23 July at 1,794–1,824 pence (the lowest price range during the window); and 68,252 shares on 24 July at 1,810–1,820 pence (VWAP 1,814.43 pence). This decline followed by stabilization may reflect broader market or sector-specific dynamics impacting insurance valuations.

Volume Weighted Average Price Analysis and Execution Quality

The VWAPs achieved each day offer insights into Peel Hunt LLP’s execution quality on behalf of Hiscox. The overall VWAP for the 334,711 shares purchased across the five-day span was 1,831.58 pence per share. Daily VWAPs ranged from a low of 1,809.74 pence on 23 July to a high of 1,861.65 pence on 20 July, representing a roughly 2.8% variance.

This pricing pattern aligns with typical market volatility for a listed insurance stock and indicates disciplined trade execution without large transactions at extreme prices. Given Hiscox’s participation in the Lloyd’s of London market and global insurance sectors, share price fluctuations can be influenced by underwriting cycles, claims experience, investment returns, and macroeconomic factors affecting insurance demand and pricing.

Regulatory Compliance and Transparency in Buyback Disclosure

Hiscox’s announcement complies fully with the UK Market Abuse Regulation (UK MAR), which enforces European Regulation (EU) No 596/2014 within the UK. Pursuant to Article 5(1)(b) of UK MAR, the company has publicly released a detailed breakdown of individual trades executed by Peel Hunt LLP in an RNS PDF document. This transparency is mandatory for UK-listed companies conducting share buybacks, enabling investors and market participants to verify transaction details.

The UK regulatory framework ensures buybacks are conducted fairly and without abuse, requiring advance programme announcements, disclosure of volume and price ranges, and prohibiting buybacks during closed periods or when inside information is held. Hiscox’s publication of daily highest, lowest, and VWAP prices allows stakeholders to assess compliance and reasonableness of execution prices relative to market conditions.

Hiscox’s Specialist Insurance Role and Capital Management Context

Hiscox Limited operates as a specialist insurer across retail, commercial, professional lines, and Lloyd’s underwriting segments. Its operations span the UK, Europe, the US, and Asia-Pacific, offering tailored insurance solutions to individuals and businesses. Listed on the London Stock Exchange, Hiscox adheres to capital requirements set by the Financial Conduct Authority and Prudential Regulation Authority, which dictate minimum solvency and capital levels.

Within this framework, share buybacks serve strategic purposes such as returning excess capital not deployable in underwriting growth, acquisitions, or investments. The timing and scale of buybacks reflect management’s view on share valuation relative to intrinsic value, capital adequacy, and competitive capital deployment opportunities. The continuation of the buyback programme suggests management’s confidence in current valuations and capital positioning to enhance shareholder value.

Impact of Share Cancellation on Share Count and Earnings Per Share

By cancelling the 334,711 repurchased Ordinary Shares, Hiscox reduces its outstanding share count. This reduction can improve earnings per share metrics on a dilution-neutral basis, assuming stable net profits. Such mechanical EPS enhancement is a common rationale for buybacks, especially when shares are perceived undervalued relative to earnings or book value.

Investors should recognize that buybacks do not increase the company’s underlying profitability. Value creation depends on acquiring shares below intrinsic value; purchases at or above fair value may be neutral or detrimental economically. Hiscox’s executive team, led by Company Secretary Marc Wetherhill and the board, is responsible for ensuring the buyback aligns with fiduciary duties and shareholder interests.

Consistency with February 2026 Buyback Authorisation

The current buyback activity stems from the programme announced on 25 February 2026, which detailed maximum share volumes, price caps, and programme duration. The July 2026 purchases were conducted within these authorised parameters, confirming the ongoing nature of the programme.

That Hiscox continues executing buybacks over five months post-authorisation indicates remaining capacity under the programme’s limits, either in volume or expenditure, or plans for future tranches. Regular disclosures of buyback tranches provide investors with updates on management’s confidence in value creation and capital return pace.

Investor Access to Detailed Transaction Records

Hiscox has made comprehensive transaction-level data publicly accessible to ensure transparency and regulatory compliance. The announcement includes a link to an RNS PDF (document 8702N_1-2026-7-26.pdf) hosted on the London Stock Exchange’s platform, detailing all trades executed by Peel Hunt LLP during the buyback week, as required by UK MAR.

Investors and analysts can review exact trade times, share quantities, and prices via this document. Such granular disclosure is standard for UK-listed companies conducting buybacks and supports transparent, orderly markets. It also aids shareholders and analysts in evaluating execution quality and modelling the company’s capital management.

Market Environment and Specialist Insurance Sector Considerations

The July 2026 buyback occurred amid broader insurance market conditions and Hiscox’s operational performance. Specialist insurers face underwriting cycles influenced by premium rates, claims trends, investment yields, and macroeconomic factors. Share prices can fluctuate with underwriting results, reserve changes, catastrophe events, interest rate shifts, and pricing cycle developments.

The share price range of 1,794 to 1,864 pence during 20–24 July 2026 reflects market valuation of Hiscox at that time. While management provided no commentary on valuation or capital strategy in the announcement, the repurchase price levels may implicitly signal confidence in the company’s intrinsic value. Investors should assess these signals alongside broader financial and market analyses.